ArticleAntimicrobial agents and chemotherapy2026
Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
We evaluated the antiviral activity of a library of 36 urea-based small-molecule cyclophilin inhibitors (SMCypIs) against human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV). Structure-spectrum analysis revealed virus-specific structural requirements for antiviral efficacy. By combining the key determinants identified for each virus, we rationally designed optimized dual-acting derivatives. Among these, the optimized compound F832/33 emerged as a potent, broad-spectrum antiviral agent with nanomolar activity against both hRSV and hMPV, submicromolar inhibition of cyclophilin (Cyp) peptidyl-prolyl isomerase (PPIase) activity, and no detectable cytotoxicity. Interestingly, no direct correlation was observed between Cyp PPIase inhibition and antiviral potency, suggesting that Cyp engagement rather than enzymatic inhibition
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.